DE602006018587D1 - Verfahren zur verbesserten isolierung rekombinant produzierter proteine - Google Patents

Verfahren zur verbesserten isolierung rekombinant produzierter proteine

Info

Publication number
DE602006018587D1
DE602006018587D1 DE602006018587T DE602006018587T DE602006018587D1 DE 602006018587 D1 DE602006018587 D1 DE 602006018587D1 DE 602006018587 T DE602006018587 T DE 602006018587T DE 602006018587 T DE602006018587 T DE 602006018587T DE 602006018587 D1 DE602006018587 D1 DE 602006018587D1
Authority
DE
Germany
Prior art keywords
produced proteins
improved isolation
recombinant produced
protein
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006018587T
Other languages
English (en)
Inventor
Stefan Winge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octapharma AG
Original Assignee
Octapharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35063154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602006018587(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Octapharma AG filed Critical Octapharma AG
Publication of DE602006018587D1 publication Critical patent/DE602006018587D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
DE602006018587T 2005-03-29 2006-03-29 Verfahren zur verbesserten isolierung rekombinant produzierter proteine Active DE602006018587D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05102475A EP1707634A1 (de) 2005-03-29 2005-03-29 Verfahren zur Isolierung von rekombinant hergestellten Proteinen
PCT/EP2006/061148 WO2006103258A1 (en) 2005-03-29 2006-03-29 Method for improved isolation of recombinantly produced proteins

Publications (1)

Publication Number Publication Date
DE602006018587D1 true DE602006018587D1 (de) 2011-01-13

Family

ID=35063154

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006018587T Active DE602006018587D1 (de) 2005-03-29 2006-03-29 Verfahren zur verbesserten isolierung rekombinant produzierter proteine

Country Status (10)

Country Link
US (2) US9388402B2 (de)
EP (4) EP1707634A1 (de)
AT (1) ATE490336T1 (de)
DE (1) DE602006018587D1 (de)
DK (1) DK1863920T3 (de)
ES (1) ES2354715T3 (de)
PL (1) PL1863920T3 (de)
PT (1) PT1863920E (de)
SI (1) SI1863920T1 (de)
WO (1) WO2006103258A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375084B2 (en) * 2006-03-07 2008-05-20 Baxter International Inc. Highly phosphorylated and sulfated recombinant factor IX
US8088900B2 (en) * 2006-03-30 2012-01-03 Novo Nordisk A/S Two-phase precipitation of proteins
CN101541950A (zh) 2006-07-13 2009-09-23 惠氏公司 糖蛋白的产生
EP1988101A1 (de) * 2007-05-04 2008-11-05 Novo Nordisk A/S Verbesserung von Faktor-VIII-Polypeptid-Titern in Zellkulturen
JP5323072B2 (ja) * 2007-07-11 2013-10-23 ノボ・ノルデイスク・エー／エス 混合方式又は多様式樹脂を使用する第ｖｉｉｉ因子の精製
EP2027875A1 (de) * 2007-08-23 2009-02-25 Octapharma AG Verfahren zur Isolierung und Reinigung eines prionenproteinfreien Target-Proteins
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
NZ586383A (en) * 2007-12-28 2012-11-30 Baxter Int Recombinant vwf formulations
US8329871B2 (en) * 2008-06-24 2012-12-11 Octapharma Ag Process of purifying coagulation factor VIII
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
EP2601932A1 (de) * 2008-10-21 2013-06-12 Baxter International Inc. Lyophilisierte rekombinante VWF-Formulierungen
ES2610529T3 (es) 2010-03-30 2017-04-28 Octapharma Ag Un procedimiento de purificación de proteínas dependientes de vitamina K, tales como el factor de coagulación IX
WO2011121031A1 (en) 2010-03-30 2011-10-06 Octapharma Ag Process for the purification of a growth factor protein
SG185038A1 (en) 2010-04-26 2012-11-29 Novartis Ag Improved cell culture medium
WO2012045769A1 (en) 2010-10-05 2012-04-12 Novo Nordisk Health Care Ag Process for protein production
CN103517919B (zh) 2011-05-13 2016-11-16 欧克塔医药公司 在重组fviii的生产中提高真核细胞生产率的方法
WO2012173260A1 (ja) 2011-06-17 2012-12-20 学校法人東日本学園・北海道医療大学 ループスアンチコアグラント検出用血液凝固時間の測定方法
KR101439634B1 (ko) * 2012-10-26 2014-09-15 주식회사 바이오에프디엔씨 항균펩타이드 베타 디펜신 3 및 그 유사체의 재조합 단백질로의 대량 생산 방법
EP3875106A1 (de) * 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Reinigung von chimären fviii-molekülen
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
TW201738256A (zh) * 2016-04-04 2017-11-01 日產化學工業股份有限公司 蛋白質產生方法
WO2018210771A1 (en) 2017-05-17 2018-11-22 Octapharma Ag Method for the production of a recombinant target protein
CN107470012B (zh) * 2017-07-05 2020-04-07 昆明理工大学 一种磷灰石纯矿物的提取方法
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
PT3884463T (pt) * 2018-11-30 2024-03-14 Amgen Inc Sistemas e métodos para deteção do efeito citopático nas células
CN111208239B (zh) * 2020-02-25 2022-10-18 浙江工业大学 一种键合态香气物质的除杂纯化方法
CN111793595A (zh) * 2020-07-23 2020-10-20 上海奥浦迈生物科技有限公司 一种hek293细胞无血清培养基
CN115299584B (zh) * 2022-08-10 2024-04-02 广东省广盐集团股份有限公司 一种具有减盐效果的盐微粒的制备方法及应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0826078B2 (ja) 1984-01-12 1996-03-13 カイロン コーポレイション フアクタ−ｖ▲ｉｉｉ▼ｃ組成物
US5045455A (en) 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
FI86885C (fi) 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
JPS6171774A (ja) 1984-09-14 1986-04-12 Sony Corp テレビジヨンカメラ装置のビ−ム電流制御装置
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
US4770999A (en) 1985-04-22 1988-09-13 Genetics Institute, Inc. High yield production of active Factor IX
ATE87663T1 (de) 1986-01-03 1993-04-15 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ- proteinen.
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
FI98829C (fi) 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
EP0251843A1 (de) 1986-06-06 1988-01-07 Transgene S.A. Verfahren zur Herstellung von Faktor VIII aus Säugerzellen
DK155388C (da) 1986-07-08 1989-10-23 Palle Pedersen Laas
EP0254076B1 (de) 1986-07-11 1991-05-08 Miles Inc. Herstellung von rekombinantem Protein
IL83192A (en) 1986-07-18 1992-11-15 Gist Brocades Nv Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies
IL84168A0 (en) 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
US4980456A (en) 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
EP0294910B1 (de) 1987-06-12 1996-09-11 Immuno Ag Proteine mit Faktor-VIII-Aktivität, Verfahren zu deren Herstellung unter Verwendung von genetisch modifizierten Zellen und diese enthaltende pharmazeutische Zusammensetzungen
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
FR2638643B1 (fr) 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
US5055555A (en) 1989-01-05 1991-10-08 Helmut Sassenfeld Purification of G-CSF
JP2865861B2 (ja) 1989-11-17 1999-03-08 ノボ ノルディスク アクティーゼルスカブ 第▲ｖｉｉｉ▼：ｃ因子活性を有するタンパク質複合体およびその製法
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
DK128093D0 (da) 1993-11-12 1993-11-12 Novo Nordisk As Hidtil ukendte forbindelser
SE9403915D0 (sv) 1994-11-14 1994-11-14 Annelie Almstedt Process A
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
US20020012991A1 (en) * 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
NZ513595A (en) 1999-02-19 2001-09-28 Octagene Gmbh Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy
US6338964B1 (en) 1999-05-07 2002-01-15 Bayer Corporation Process and medium for mammalian cell culture under low dissolved carbon dioxide concentration
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
PT1210411E (pt) * 1999-08-25 2006-12-29 Immunex Corp Composições e métodos para cultura celular melhorada
EE200200538A (et) 2000-03-22 2004-04-15 Octagene Gmbh Rekombinantsete verehüübimisfaktorite produtseerimine inimese rakuliinides
WO2005058930A2 (en) * 2003-12-11 2005-06-30 Proteomtech Inc. Methods for production of recombinant vascular endothelial cell growth inhibitor

Also Published As

Publication number Publication date
WO2006103258A1 (en) 2006-10-05
EP2258860A1 (de) 2010-12-08
EP1863920B1 (de) 2010-12-01
PL1863920T3 (pl) 2011-05-31
US20170183703A1 (en) 2017-06-29
ES2354715T3 (es) 2011-03-17
US9388402B2 (en) 2016-07-12
US20090088370A1 (en) 2009-04-02
EP1707634A1 (de) 2006-10-04
EP3467116A1 (de) 2019-04-10
PT1863920E (pt) 2011-01-19
EP1863920A1 (de) 2007-12-12
DK1863920T3 (da) 2011-03-14
ATE490336T1 (de) 2010-12-15
SI1863920T1 (sl) 2011-03-31
US10626431B2 (en) 2020-04-21

Similar Documents

Publication Publication Date Title
DE602006018587D1 (de) Verfahren zur verbesserten isolierung rekombinant produzierter proteine
BR122019022434B8 (pt) método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular
PE20140867A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso
BRPI0516572A (pt) métodos e composições para melhorar a produção de proteìnas recombinantes
EP2395091A3 (de) Pflanzen mit verbesserten Ertragseigenschaften und Verfahren zu deren Herstellung
EA201100146A1 (ru) Растения, имеющие улучшенные характеристики урожайности, и способ их получения
MX2007005132A (es) Medios libres de proteina animal para cultivo de celulas.
PE20070796A1 (es) Metodo de produccion proteica utilizando compuestos anti-senescencia
DE69838383D1 (de) Kulturmedium mit sojabohnenextrakt als aminosäuren-quelle und ohne proteinkomplexe tierischen ursprungs
DK1929001T3 (da) Nye dehydrogenaser, disses derivater og en fremgangsmåde til fremstilling af optisk aktive alkanoler
MX2009011362A (es) Uso de temperatura baja y/o ph bajo en el cultivo celular.
EA201001435A1 (ru) Клетка, ферментирующая сахар-пентозу
UA92157C2 (ru) Способ продуцирования гормона роста
WO2006128764A3 (en) Process for cultivating animal cells comprising the feeding of plant-derived peptones
EP2189534A3 (de) Pflanzen mit SYT-Polypeptid transformiert die unter abiotischem Stress einen erhöhten Ertrag aufweisen und Methoden zur Herstellung dieser Pflanzen
MX2009007308A (es) Plantas que tienen rasgos relacionados con el rendimiento mejorado y/o resistencia al estres abiotico aumentada y un metodo para obtener las mismas.
MX2012003451A (es) Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para prepararlas.
AU2008220715A8 (en) Plants having enhanced yield-related traits and a method for making the same
WO2010023320A3 (en) Plants having enhanced yield-related traits and a method for making the same
WO2009066320A3 (en) Gcsf fusion protein systems suitable for high expression of peptides
DE60307615D1 (de) Zellkulturmedium
EP2998401A3 (de) Pflanzen mit verbesserten ertragseigenschaften und verfahren zur herstellung davon
EA201070229A1 (ru) Нуклеотидные последовательности msca1, влияющие на мужскую фертильность растений, и способ их применения
ATE451457T1 (de) Verfahren zur dipeptidherstellung
ATE536347T1 (de) Effiziente herstellung heterologer proteine unter verwendung von mannosyltransferaseinhibitoren